Braidwell LP Cuts Stake in Oruka Therapeutics, Inc. $ORKA

Braidwell LP cut its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 3.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,524,842 shares of the company’s stock after selling 47,584 shares during the period. Braidwell LP owned approximately 4.07% of Oruka Therapeutics worth $17,093,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ORKA. Geode Capital Management LLC raised its holdings in Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after acquiring an additional 354,821 shares during the last quarter. Franklin Resources Inc. increased its holdings in Oruka Therapeutics by 40.6% in the 2nd quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock worth $11,355,000 after buying an additional 292,421 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in Oruka Therapeutics during the 1st quarter valued at about $2,505,000. Affinity Asset Advisors LLC lifted its stake in Oruka Therapeutics by 47.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock valued at $5,595,000 after acquiring an additional 176,664 shares during the period. Finally, Cable Car Capital LP boosted its holdings in shares of Oruka Therapeutics by 33.3% during the 2nd quarter. Cable Car Capital LP now owns 600,000 shares of the company’s stock valued at $6,726,000 after acquiring an additional 150,000 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ORKA. Barclays began coverage on shares of Oruka Therapeutics in a report on Monday, October 13th. They set an “overweight” rating and a $48.00 price objective for the company. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Guggenheim assumed coverage on Oruka Therapeutics in a research report on Monday, October 27th. They issued a “buy” rating and a $60.00 target price on the stock. HC Wainwright cut their price target on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.14.

Oruka Therapeutics Trading Down 0.1%

NASDAQ ORKA opened at $30.18 on Friday. Oruka Therapeutics, Inc. has a 12 month low of $5.49 and a 12 month high of $32.28. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -15.88 and a beta of -0.41. The company’s 50 day moving average is $27.78 and its two-hundred day moving average is $18.89.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. Sell-side analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.